November 08, 2016

Now published: ESC/EAS Consensus Statement on PCSK9

EAS, in collaboration with the European Society of Cardiology (ESC), have published a consensus document is to discuss the appropriate clinical use of PCSK9 antibodies in patients at very high cardiovascular risk who have substantially elevated LDL-C levels on maximal statin/ezetimibe therapy. Consistent with European guidelines, this consensus document focuses on three priority groups: (i) patients at very high risk not at LDL-C goal, i.e. with documented ASCVD; (ii) patients with FH without ASCVD; and (iii) patients in any of these groups with statin intolerance. This Open Access publication is now available from European Heart Journal.

The authors are Ulf Landmesser, M. John Chapman, Michel Farnier, Baris Gencer, Stephan Gielen, G. Kees Hovingh, Thomas F. Lüscher, David Sinning, Lale Tokgözoglu, Olov Wiklund, Jose Luis Zamorano, Fausto J. Pinto, and Alberico L. Catapano on behalf of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

To view the publication in full and to download PDF >>

Latest news from the Cardiovascular Gene Annotation Initiative

Read about the latest progress in Gene annotation in the November Newsletter from the Cardiovascular Gene Annotation Initiative funded by the British Heart Foundation, BHF. 

The newsletter includes updates on Gene annotation, molecular interaction data and links to an informative blog describing Gene Ontology and the job of a biocurator.

To the November newsletter online >>

EAS meetings coming up:

Registration still open!

The Symposium will summarize and discuss up-to-date information on FH and bring together leaders in the field. One of the main themes of the Symposium is to facilitate collaboration between experts, with particular focus on the region of Central and Eastern Europe, and to invite them for closer cooperation with EAS in the Central & Eastern European Key Opinion Leader Summit.

To meeting website >>
Programme >>
Online registration >>

EAS 2017, Prague:

Keynote Lecturer Professor Göran Hansson

Göran Hansson, Stockholm, Sweden

Keynote Lecture, Monday April 24

EAS is delighted to announce that the Keynote Lecture at the 2017 EAS Congress in Prague will be given by Professor Göran K. Hansson, Professor of Experimental Cardiovascular Research, Karolinska Institutet, Sweden.


Present your own work and interact with leading experts in the field - Abstract sumbission open until November 28!

The EAS 2017 Scientific Committee has created an innovative programme featuring influential speakers in their respective fields. EAS 2017 Prague welcomes a distinguished international faculty to share their pioneering perspectives on the latest developments in basic research and clinical practice in atherosclerosis and cardiovascular disease.

Submit your abstract >>

Read more about Fellowships and how to apply >>

Read more about Travel grants and how to apply >>

EAS membership benefits >>

Find out more

About EAS

EAS Membership

EAS Congress

EAS Educational Initiatives

EAS Publications

European Lipoprotein Club (ELC)

EAS-FH Studies Collaboration (FHSC)


About this email

You have received this email because you are currently subscribed to receive general correspondence from EAS.


European Atherosclerosis Society
Mässans Gata 18
Box 5243
SE-402 24, Gothenburg SWEDEN

Organisation number: 802418-0427

This email was sent to '@@email@@' from European Atherosclerosis Society.
If you wish to stop receiving email from us, you can simply remove yourself by visiting: @@unsubscribe_url@@


European Atherosclerosis Society © 2016